共 7 条
[1]
Kalinsky K(2021)21-Gene assay to inform chemotherapy benefit in node-positive breast cancer N Engl J Med. 385 2336-2347
[2]
Farley CR(2023)To dissect or not to dissect: Can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with clinically node negative breast cancer? Ann of Surg Oncol. 38 3987-3998
[3]
Bassett RL(2020)Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE) J Clin Oncol. 41 LBA500-undefined
[4]
Meric-Bernstam F(2023)Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial J Clin Oncol. 23 7843-undefined
[5]
Johnston SRD(2022)Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers Int J Mol Sci. undefined undefined-undefined
[6]
Slamon DJ(undefined)undefined undefined undefined undefined-undefined
[7]
Addanki S(undefined)undefined undefined undefined undefined-undefined